Short report: Contribution of quantitative real-time polymerase chain reaction to follow-up of visceral leishmaniasis patients treated with meglumine antimoniate

Am J Trop Med Hyg. 2009 Dec;81(6):1004-6. doi: 10.4269/ajtmh.2009.09-0285.

Abstract

Forty-two patients with visceral leishmaniasis in Tunisia were treated with meglumine antimoniate and followed-up for clinical improvement and blood parasite load determined by quantitative real-time polymerase chain reaction (PCR). Parasite loads before treatment ranged from 27 to 5.3 x 10(7) parasites/mL. At the end of treatment, parasite load decreased significantly in 39 cured patients (P < 0.001). The decrease in parasite load after treatment was greater than 99% for 34 patients and PCR results became negative in 23 of them. Two patients without clinical improvement showed no or slight decreases in parasite load (209 versus 202 parasites/mL and 1,765 versus 146 parasites/mL). One patient showed had a relapse seven months after showing a good response to treatment. His parasitemia remained high despite a sharp decrease (5.2 x 10(5) versus 5.9 x 10(3) parasites/mL).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiprotozoal Agents / therapeutic use*
  • DNA, Protozoan / blood
  • Follow-Up Studies
  • Humans
  • Leishmaniasis, Visceral / drug therapy*
  • Meglumine / therapeutic use*
  • Meglumine Antimoniate
  • Organometallic Compounds / therapeutic use*
  • Polymerase Chain Reaction*

Substances

  • Antiprotozoal Agents
  • DNA, Protozoan
  • Organometallic Compounds
  • Meglumine
  • Meglumine Antimoniate